BASAGLAR KWIKPEN U-100 (insulin glargine) is associated with Lower Hospital Readmission Rates for Type II Diabetes Patients based on Real World Evidence Study of Medicare Claims Data


In BASAGLAR KWIKPEN, Type II Diabetes

Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education


Background:

Type II Diabetes is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. BASAGLAR KWIKPEN U-100(insulin glargine) is a disposable, single-patient-use prefilled insulin pen. BASAGLAR was the first insulin product approved through an abbreviated approval pathway by the FDA. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of BASAGLAR KWIKPEN U-100(insulin glargine) within 7 days of hospitalization was associated with lower hospital readmission rates for Type II Diabetes. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.

Methods:

We conducted a retrospective study using Dexur’s analysis of Real-World Evidence from Medicare Claims data, for hospitalizations between January 2019 to September 2019. Our methodology criteria was as follows:

  1. Inclusion Criteria: Selected Medical Hospitalizations with Primary Diagnosis with Type II Diabetes codes (Listed in table below)

  2. Stratified Selected population into cohorts

    1. Type II Diabetes who dispensed BASAGLAR KWIKPEN U-100(insulin glargine) within 7 Days of Hospitalization using Part D drugs claims database

    2. Type II Diabetes patients who did not dispense BASAGLAR KWIKPEN U-100(insulin glargine) within 7 Days of Hospitalization

  3. 30 Day readmission rates were analyzed for both population cohorts

Results:

Overall, BASAGLAR KWIKPEN U-100(insulin glargine) was associated with lower hospital readmission rates for all Primary ICD Diagnosis Codes examined. For patients whose primary ICD Diagnosis was “Type 2 diabetes mellitus with hyperglycemia” (E1165) and whenBASAGLAR KWIKPEN U-100(insulin glargine) was used within 7 days of hospitalization, the readmission rate was 17.98% compared to the cohort where BASAGLAR KWIKPEN U-100(insulin glargine) was not used, whose readmission rate was 22.95%. The readmission odds ratio for these cohorts was 0.74. The use of BASAGLAR KWIKPEN U-100(insulin glargine) was associated with a 26% lower readmission rate when used within 7 days of hospitalization. The full list of studied ICD codes, readmission rates, odds ratios, confidence intervals, and percentage reduction in readmission with BASAGLAR KWIKPEN U-100(insulin glargine) is shown below.


= Data Available for Premium Subscribers. Please email dexur@dexur.com for subscription information

Primary ICD Diagnosis Code Primary ICD Diagnosis Code Description Total Hospitalizations without BASAGLAR Readmission without BASAGLAR Readmission Rate without BASAGLAR Total Hospitalizations with BASAGLAR Readmission with BASAGLAR Readmission Rate with BASAGLAR Readmission Odds Ratio Reduction in Readmission with BASAGLAR (%) Confidence Interval (-) Confidence Interval (+)
E1165 Type 2 diabetes mellitus with hyperglycemia 13,486 3,083 22.86% 552 91 16.49% 0.67 33% -6.70% -6.05%
E1110 Type 2 diabetes mellitus with ketoacidosis without coma

Dexur also leveraged Medicare claims data to understand what percentage of patients hospitalized with Type 2 Diabetes at major Hospitals were not prescribed Basaglar within 7 days of discharge.

ICD CODE Hospital Hospitalizations with Type 2 Diabetes % of Hospitalizations without Basaglar
E1165 Montefiore Medical Center, BRONX, NY, 10467 86 88.37%
AdventHealth Orlando, ORLANDO, FL, 32803 63 84.13%
Lehigh Valley Hospital - Cedar Crest, ALLENTOWN, PA, 18103 48 79.17%
E1110 AdventHealth Orlando, ORLANDO, FL, 32803 58 82.76%
Vidant Medical Center, GREENVILLE, NC, 27834 36 72.22%
Memorial Hermann Hospital System, HOUSTON, TX, 77008 34 70.59%

Conclusions:

According to analysis of Real-World Evidence of Medicare Claims data, for hospitalizations between January 2019 to September 2019, the use of BASAGLAR KWIKPEN U-100(insulin glargine) within 7 days of hospitalization can lead to substantial reductions in hospital readmission rates of Type II Diabetes patients.